Lightcast Announces Limited Commercial Release of Envisia™ Single-Cell Functional Analysis Platform for Antibody Discovery
Lightcast reaches an exciting milestone with the limited commercial release of its novel Envisia™ platform.
News & Insights
OrganOx Announces Second Private Placement Closing, Investments by Intuitive Ventures and Terumo Ventures
OrganOx to benefit from Intuitive Ventures’ and Terumo Ventures’ unique operating and clinical experience
Oxford PV, Trina Solar enter patent licensing agreement for perovskite-silicon tandem solar
Perovskite solar specialist Oxford PV has signed a patent licensing agreement with Chinese module manufacturer Trina Solar. The agreement covers the manufacture and sale of perovskite-based photovoltaic products in China and includes an additional right to sublicense.
OrganOx Announces $142 Million Equity Financing Led by HealthQuest Capital
- OrganOx has completed a $142m primary and secondary equity financing to accelerate the rollout of its metra devices.
- The oversubscribed round was led by external investor HealthQuest, alongside new investors Sofina, Soleus Capital, and Avidity Partners and with support from existing investors BGF and Lauxera Capital Partners.
The Lancet publishes results of a landmark clinical study that supports the ability of Caristo’s CaRi-Heart® AI technology to quantify coronary artery inflammation and accurately predict cardiac events.
- Leading medical journal, The Lancet, has published the findings of the 40,000 patient ORFAN study demonstrating the ability of Caristo’s CaRi-Heart FAI-Score to predict fatal and non-fatal cardiac events.
- Caristo’s AI-Risk model, CaRi-Heart Risk Score, outperformed other scores in routine clinical use for prediction of cardiac mortality, and when presented to clinicians, resulted in changes of management decision in 45% of the patients.